Moody Lynn & Lieberson LLC raised its stake in shares of Diplomat Pharmacy Inc. (NYSE:DPLO) by 1.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,105 shares of the company’s stock after buying an additional 190 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Diplomat Pharmacy were worth $529,000 as of its most recent filing with the SEC.
Several other hedge funds have also modified their holdings of DPLO. BlackRock Fund Advisors raised its position in shares of Diplomat Pharmacy by 124.6% in the first quarter. BlackRock Fund Advisors now owns 2,387,152 shares of the company’s stock worth $65,408,000 after buying an additional 1,324,293 shares during the period. Hermes Investment Management Ltd. raised its position in shares of Diplomat Pharmacy by 15.2% in the second quarter. Hermes Investment Management Ltd. now owns 884,459 shares of the company’s stock worth $30,956,000 after buying an additional 116,920 shares during the period. JPMorgan Chase & Co. raised its position in shares of Diplomat Pharmacy by 21.4% in the first quarter. JPMorgan Chase & Co. now owns 281,635 shares of the company’s stock worth $7,718,000 after buying an additional 49,630 shares during the period. Redwood Investments LLC raised its position in shares of Diplomat Pharmacy by 27.5% in the second quarter. Redwood Investments LLC now owns 127,107 shares of the company’s stock worth $4,449,000 after buying an additional 27,378 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of Diplomat Pharmacy during the first quarter worth about $2,191,000. Hedge funds and other institutional investors own 75.81% of the company’s stock.
Diplomat Pharmacy Inc. (NYSE:DPLO) traded down 1.20% during midday trading on Wednesday, hitting $28.06. The stock had a trading volume of 482,077 shares. Diplomat Pharmacy Inc. has a 12 month low of $22.41 and a 12 month high of $38.94. The stock has a 50 day moving average of $29.56 and a 200 day moving average of $32.13. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of 43.17 and a beta of 1.06.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Tuesday, August 9th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The firm earned $1.09 billion during the quarter, compared to the consensus estimate of $1.12 billion. Diplomat Pharmacy had a net margin of 1.08% and a return on equity of 11.57%. The company’s revenue was up 34.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.16 earnings per share. Analysts expect that Diplomat Pharmacy Inc. will post $0.94 EPS for the current fiscal year.
A number of brokerages recently issued reports on DPLO. Zacks Investment Research lowered Diplomat Pharmacy from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Cowen and Company began coverage on Diplomat Pharmacy in a research note on Thursday, June 23rd. They issued a “market perform” rating and a $37.00 target price for the company. Leerink Swann raised their target price on Diplomat Pharmacy from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 10th. Mizuho raised their target price on Diplomat Pharmacy from $33.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 10th. Finally, Credit Suisse Group AG restated a “hold” rating and issued a $30.00 target price on shares of Diplomat Pharmacy in a research note on Friday, September 16th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $37.50.
In other Diplomat Pharmacy news, EVP Atheer A. Kaddis sold 20,000 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $30.12, for a total value of $602,400.00. Following the completion of the transaction, the executive vice president now owns 20,000 shares in the company, valued at $602,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Atheer A. Kaddis sold 12,325 shares of the company’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $35.76, for a total transaction of $440,742.00. Following the completion of the transaction, the executive vice president now owns 12,325 shares of the company’s stock, valued at approximately $440,742. The disclosure for this sale can be found here. Corporate insiders own 35.40% of the company’s stock.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc. (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.